Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Nalbuphine as Adjuvants to Bupivacaine in Infraclavicular Block
NCT07279727Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in regional anesthesia comparing Nalbuphine group with Dexmedetomidine group (2 arms). Primary endpoint: Duration of Analgesia at 24 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nalbuphinedexmedetomidine
03
Conditions
regional anesthesia
Beyond the preview
Go deeper on NCT07279727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279727.